[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349807-105":59,"doc-detail-349807-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","association-of-pcsk9-inhibitors-versus-statins-with-cancer-incidence-a-target-trial-emulation","Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation","","Background: The relationship between PCSK9 inhibitors (PCSK9i) and cancer incidence remains insufficiently understood. This study evaluates the association between PCSK9i use and cancer risk compared with statin therapy. Methods: A retrospective cohort analysis with target trial emulation was conducted using de-identified TriNetX electronic health records from July 2015 to June 2023. Adults initiating PCSK9i were propensity-score matched 1:1 with new statin users without prior statin use. The primary outcome was any malignant neoplasm (ICD-10 C00–C97) over 5-year follow-up.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-of-pcsk9-inhibitors-versus-statins-with-cancer-incidence-a-target-trial-emulation/349807/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-of-pcsk9-inhibitors-versus-statins-with-cancer-incidence-a-target-trial-emulation/349807.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about PCSK9 inhibitors and cancer?","Question",{"text":113,"@type":114},"The study investigates whether PCSK9 inhibitor use is associated with cancer incidence compared with statin therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants selected and compared in the analysis?",{"text":118,"@type":114},"Adults with indications for lipid-lowering therapy who initiated PCSK9i were propensity-score matched 1:1 with new statin users with no prior statin use, using TriNetX records.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the primary outcome and how long was follow-up?",{"text":122,"@type":114},"The primary outcome was incidence of any malignant neoplasm (ICD-10 C00–C97), assessed over a 5-year follow-up period.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349807,1790431525,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Huang et al. Cardio-Oncology (2026) 12:19 [https://doi.org/10.1186/s40959-025-00436-0](https://doi.org/10.1186/s40959-025-00436-0)  \nCardio-Oncology  \nRESEARCH Open Access  \nAssociation of PCSK9 inhibitors versus statins   with cancer incidence: a target trial emulation  \nChi-Hsien Huang1,2,3*†, Shiow-Ing Wang4,5†, Frank S. Fan6, Hsueh-Ju Lu6,7 and James Cheng-Chung Wei5,8,9,10,11*  \nAbstract  \nBackground The relationship between PCSK9 inhibitors (PCSK9i) and cancer incidence remains poorly understood. This study is to investigate the association between PCSK9i use and cancer risk compared to statin therapy.  \nMethods We conducted a retrospective cohort study using target trial emulation principles on de-identified electronic health records from the TriNetX network (July 2015 – June 2023) . Adults with indications for lipid-lowering therapy who initiated PCSK9i (alirocumab, evolocumab, or inclisiran) or statins (no prior statin use) were included. New PCSK9i users were propensity-score matched 1:1 with new statin users. The primary outcome was the incidence of any malignant neoplasm, defined by ICD-10 codes C00–C97, over a 5-year follow-up period.  \nResults A total of 43,935 PCSK9i users and 6,127,401 statin users were identified; after matching, 43,933 PCSK9i users were compared with 43,933 statin users. PCSK9i use was associated with a significantly lower risk of overall cancer (HR 0 . 804, 95% CI 0.760–0. 850) compared to statin use. Notably, PCSK9i users had lower incidence of cancers ofthe digestive organs (HR 0 . 647, 95% CI 0 .548–0. 763), respiratory and intrathoracic organs (HR 0 . 691, 95% CI 0.578–0. 827), melanoma and other skin cancers (HR 0 . 789, 95% CI 0 .704–0. 885), female genital organs (HR 0 . 735, 95% CI 0.558– 0. 968), urinary tract (HR 0 . 719, 95% CI 0.590–0. 875), and ill-defined sites (HR 0 . 660, 95% CI 0.578–0. 755) compared to statin users.  \nConclusions This study revealed a significant association between PCSK9i use and reduced cancer incidence compared with statin use, suggesting effects beyond lipid regulation.  \nKeywords PCSK9 inhibitors, Cancer incidence  \n†Chi-Hsien Huang and Shiow-Ing Wang contributed equally to this work and share first authorship.  \n*Correspondence:  \nChi-Hsien Huang  \n[evaairgigaa@gmail.com](evaairgigaa@gmail.com); [ed103520@edah.org.tw](ed103520@edah.org.tw)  \nJames Cheng-Chung Wei  \n[jccwei@gmail.com](jccwei@gmail.com)  \n1Department of Family Medicine and Community Medicine, E-Da Hospital, I-Shou University, Kaohsiung City, Taiwan  \n2School of Medicine, College of Medicine, I-Shou University, Kaohsiung City, Taiwan  \n3College of Nursing, Kaohsiung Medical University, Kaohsiung City, Taiwan  \n4Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan  \n5Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City 40201, Taiwan  \n6Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan  \n7School of Medicine, Chung Shan Medical University, Taichung, Taiwan 8Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan  \n9Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan  \n10Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan  \n11Office of Research and Development, Asia University, Taichung, Taiwan  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to ","cbCaihCyAp3K5X3n","https://ap.wps.com/l/cbCaihCyAp3K5X3n","pdf",1606284,11,"English","# Abstract\n# Introduction\n## Background on PCSK9 inhibitors and cardiovascular outcomes\n## Emerging evidence linking PCSK9 to cancer biology","[{\"question\":\"What question does the study address about PCSK9 inhibitors and cancer?\",\"answer\":\"The study investigates whether PCSK9 inhibitor use is associated with cancer incidence compared with statin therapy.\"},{\"question\":\"How were participants selected and compared in the analysis?\",\"answer\":\"Adults with indications for lipid-lowering therapy who initiated PCSK9i were propensity-score matched 1:1 with new statin users with no prior statin use, using TriNetX records.\"},{\"question\":\"What was the primary outcome and how long was follow-up?\",\"answer\":\"The primary outcome was incidence of any malignant neoplasm (ICD-10 C00–C97), assessed over a 5-year follow-up period.\"}]","Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation | PDF",1790085664,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72bb0ddb01bb8772ff56e0c466cfe81a.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32d1324c4ea6c41636783570f47cb42f.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2e9df0204bf60fef8c3488c658ed5e2.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b72f6d1948faa15de7495a4b8cf08e20.webp",980,1306]